Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil

Archives of Dermatology

Volumn 148, Issue 8, 2012, Pages 887-888

  Haeberle, M Tye ^a   Adams, William B ^a   Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CREATININE; CRYOGLOBULIN; DAPSONE; IBUPROFEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SERTRALINE; ZOLPIDEM;

ABDOMINAL CRAMP; ADULT; ANAMNESIS; ARTICLE; BASEMENT MEMBRANE; BONE MARROW SUPPRESSION; CASE REPORT; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; ERYTHROCYTE; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LABORATORY TEST; LEUKOCYTOCLASTIC VASCULITIS; MALE; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; SEROLOGY; SKIN BIOPSY; SMALL VESSEL VASCULITIS; VOMITING;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SKIN DISEASES, VASCULAR; VASCULITIS;

EID: 84865681925     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3037     Document Type: Article

References (10)

1. Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45(1):3-13.
2. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131(2):193-197.
3. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, cor-ticosteroid- sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127(4):515-522.
4. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005;20(12):2725-2732.
5. Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis. 2007; 66(6):798-802.
6. Hiemstra TF, Walsh M, Mahr A, et al European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381-2388.
7. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol. 2000; 143(6):1324.
8. Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol. 2006;45(10):1224-1227.
9. Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol . 2009;60(2):183- 199, quiz 200-202.
10. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20(4):229-238.